,41 Regarding SGLT2 inhibitors, its use for patients with HFpEF is hypothesized to improve HF outcomes through mechanisms such as rapid reduction of pulmonary artery pressure, weight loss, and increased myocardial energy production.42 Here, SLC5A2 is linked to hydrops fetalis.